Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Phase 3 study in rheumatoid arthritis after inadequate response to TNF inhibitors
2012-002323-15Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients achieving ACR20 response. Started Dec 2012; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-002323-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002323-15.